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Abstract
Background: Wilson disease (WD) is an inherited neurometabolic disorder that results in excessive copper deposition in the liver and the brain, affecting children
and young adults. Without treatment the disease is invariably fatal. Though treatments for WD have been available since the 1950s, the disease continues to be
associated with considerable morbidity and mortality because of missed diagnosis, and delayed or inadequate treatment. In this paper we survey WD-related
literature in order to review recent advances in WD treatment.
Methods: We performed a literature search using the PubMed database for articles relating to WD and its medical treatment. We reviewed the articles, and cross-
references of relevant articles, to summarize the current practices for treatment of WD.
Results: The survey shows that if WD is properly treated, in most patients the liver can be stabilized, even severe neurological disability reversed, and patients can
resume normal lives.
Discussion: Medical treatment for WD includes use of copper chelators (penicillamine, trientine, dimercaprol, dimercaptopropane sulfonate, and ammonium
tetrathiomolybdate) and drugs that decrease gastrointestinal copper absorption. Our knowledge of the treatment approaches has benefited from the large systematic
clinical studies that have been conducted over the last decade. For each drug used to treat WD, we surveyed its development, indication for use, dosing, efficacy, and
adverse effects.
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Introduction
Wilson disease (WD) was first described by S.A.K. Wilson, in 1912,
as a new syndrome of familial lentiform degeneration and liver cirrhosis,
which was invariably fatal.1 For nearly half a century thereafter, the
cause of the disease remained unclear and patients continued to die
without definitive treatment. Things changed rapidly once John
Nathaniel Cumings demonstrated that WD resulted from excessive
copper deposition in the liver and the brain.2 This finding immediately
suggested copper chelation as a treatment. The first copper chelator used
was intramuscular dimercaprol, which not only increased urinary copper
excretion but also resulted in remarkable clinical improvement.3–5
However, it was soon realized that dimercaprol was not a tenable long-
term treatment option as it was associated with considerable adverse
effects, rapid drug tolerance, and waning clinical benefits. It was
penicillamine, introduced by John Walshe in 1955, that changed the
prognosis for WD, making survival as well as dramatic and sustained
clinical recovery possible. Subsequently, other effective medical treat-
ments were introduced, and liver transplant became an option for
patients with life-threatening liver failure or those who were intolerant to
medical treatment.6,7
WD was the first of a number of neurometabolic diseases that
are now treatable. However, monitoring and titrating treatment of
WD remains complex, and the disease is still associated with con-
siderable disability and even deaths due to delayed diagnosis and
inadequate treatment. Significant reasons for this are the disease’s
rarity (prevalence of one in 30,000), multisystemic involvement, and
clinical heterogeneity, which make it difficult for a single practitioner
to develop sufficient expertise to diagnose and treat WD through
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clinical experience alone.8 The disease’s rarity also makes large and
comparative clinical trials of WD and its treatment prohibitive, and
most studies involve a handful, or a few tens, of subjects (only over the
last decade have larger trials with 100+ subjects become somewhat
more common). Therefore it is of value to pool the knowledge gained
through studies at the numerous clinical and research centers across
the world, and disseminate it to medical practitioners who can then
apply it in treating WD patients.
In this article, we review and summarize the current treatments
available for WD. We focus on definitive medical treatments that
directly address the root issue of excessive copper deposition in WD.
Readers interested in symptomatic treatment for liver failure (for
instance, drugs to reduce portal hypertension, or intervention for
portosystemic varices), or neurological symptoms (for example,
dopaminergic drugs and botulinum toxin for various movement
disorders; or medication for depression and behavioral problems) are
refereed to recent reviews by Pfeiffenberger et al.9 and Litwin et al.,10
respectively. The use of liver transplant in patients with WD is also
outside the scope of this article and has been reviewed elsewhere.11–13
Methods
We searched the PubMed database using variant names of the
disease, ‘‘Wilson’s disease,’’ ‘‘Wilson disease,’’ and ‘‘hepatolenticular
degeneration,’’ in combination with treatment-related terms, ‘‘treat-
ment,’’ ‘‘BAL,’’ ‘‘dimercaprol,’’ ‘‘penicillamine,’’ ‘‘dimercaptopropane
sulphonate,’’ ‘‘unithiol,’’ ‘‘trientine,’’ ‘‘zinc,’’ and ‘‘tetrathiomolyb-
date.’’ We restricted our search to English language articles involving
human subjects in which these terms appeared in the title or abstract,
and which were published between January 1, 1950, and the date of
search. The search was first performed in May 2017 and the results
were subsequently updated to be current until October 15, 2017.
The search identified 1,184 candidate articles. We then screened the
titles and abstracts of these papers to check if they fell within the scope
of this review. At this stage 666 articles were excluded because of lack
of relevance (not related to WD; not related to treatment of WD;
related to animal studies, unestablished treatments, liver transplant,
apheresis, or symptomatic medical or surgical interventions). An addi-
tional 74 articles had to be excluded since their abstracts or full texts
were not accessible; these tended to be among the older articles in the
database and their exclusion is not expected to affect the substance of
this review.
The remaining 444 papers were selected for further review. Of these
about 70% (315) were case reports or cohort studies. In addition, there
were 95 review articles; 30 letters, editorials or commentaries; two
guidelines;14,15 and two systematic reviews.16,17 Among the 315 patient
studies 78% (247 studies) included fewer than 30 participants, and only
6% (18 studies) had 100 or more subjects (notably, 13 of these studies
were published within the last decade). Except for one randomized
control trial,18 all the patient studies were cross-sectional or long-
itudinal observational studies. We also reviewed cross-references of
selected publications for added perspective.
Results
The aim of the survey was to address two main questions: what
patient population should be treated and what are the available
treatment options. Below we summarize our findings and outline the
history of development, indication of use, dosing recommendations,
efficacy, and adverse effects associated with each drug currently used
for definitive medical treatment of WD.
Treatment populations
Copper is an essential micronutrient. The normal diet contains
1–2 mg/day of copper of which 85–95% is excreted into the bile by
the liver. Urinary excretion of copper is negligible and there are no
insensible losses.19 It is estimated that because of impaired biliary
excretion of copper, patients with WD may gain up to 1 mg of copper
per day.20 The copper accumulation commences at birth but patients
usually remain asymptomatic for the first one to two decades of life.
Over time, copper-related tissue injury leads to symptoms and signs
of liver failure, extrapyramidal syndromes, or behavioral problems.
Copper also deposits in the cornea, although it does not impair vision.
Eventually, unless treated, continued copper accumulation leads to
death from progressive liver failure or from complications of severe
neurological disability.8
The aim of treatment is to remove the accumulated copper and
prevent further copper gain. While justification of treatment in symp-
tomatic patients is obvious, treatment of patients who have not yet
developed symptoms is also needed in order to restore normal copper
balance and pre-empt symptom onset. In both symptomatic and
asymptomatic patients, treatment needs to be continued lifelong to
prevent a positive copper balance from dietary copper gain.
Patients heterozygous for ATP7b mutations (one normal and one
abnormal ATP7b allele) do not have WD and do not require treat-
ment (Table 1).14,15,21,22
Treatment options
Copper is ubiquitous in food and water supplies. A low-copper diet
does not prevent copper gain and is unnecessary.23 During the initial
period of copper chelation in symptomatic patients some clinicians
suggest avoidance of copper-rich foods such as shellfish, liver, cocoa,
nuts, chocolate, mushroom, and dried fruits. These dietary restrictions
may be relaxed after a few months.14,15,23
Medical treatment options of WD are drugs that chelate copper
and those that prevent gastrointestinal copper absorption. In order of
introduction, the available copper chelators are dimercaprol, peni-
cillamine, dimercaptopropane sulfonate, and trientine. Zinc adminis-
tered in the form of zinc salts decreases intestinal dietary copper
absorption. Ammonium tetrathiomolybdate (TTM) is a promising
newer therapy that both chelates copper and blocks copper absorption
in the intestine (Table 2). Interestingly, all these drugs have been
developed by individuals or small research groups rather than large
multinational pharmaceutical companies.14,15,24,25
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Dimercaprol. Dimercaprol (2,3-dimercapto-1-propanol), or British
anti-Lewisite (BAL), was developed in 1940 by Sir Rudolph Albert
Peters’ group at the University of Oxford, UK, amid great secrecy, as
an antidote to an arsenical chemical weapon (lewisite) during World
War II.26 BAL is an alcohol with two substituted sulfhydryl groups
(dithiol) that form a stable five-membered ring with trivalent arsenic,
and neutralize its toxicity. BAL was chosen over other dithiols as it
could be safely applied on human skin and was effective. It is estimated
that almost 56 million tubes of BAL ointment were distributed among
US troops and there were contingency plans to produce 200,000
pounds of the drug annually, in case arsenic was used as a chemical
war agent.27 Shortly after its introduction as an antidote to arsenic,
BAL was shown to increase excretion of other metals such as gold,
mercury, silver, and copper. There was also evidence to suggest that
BAL promoted excretion of copper in preference to metals such as iron
and zinc.3
Therefore, once it was demonstrated that WD resulted from
excessive copper deposition, John Cumings, at the National Hospital
in London, and Derek E. Denny-Brown and Huntington Porter, at
the Boston City Hospital and Harvard Medical School in Boston,
independently thought of using BAL, and showed that BAL led to
copper excretion and clinical benefit in WD.3–5,28 Denny-Brown and
Table 1. Treatment Options and Strategies in Wilson Disease14,15,25
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Do not have Wilson disease
and do not require treatment
1Only mainline treatment options are listed here. See text for discussion of dimercaprol (BAL) and tetrathiomolybdate.
2Combination therapy of oral chelator and zinc is generally not recommended (see text).
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Porter also showed dramatic improvement in behavior and movement
disorders in five severely incapacitated patients with WD on prolonged
use of BAL. This work generated considerable enthusiasm and interest
in both the medical fraternity and the popular press, and it is thought
to have contributed to the evolution of neurology from a descriptive
and palliative discipline to a therapeutic branch of medicine.3,5,28
BAL was given as repeated courses of multiple daily injections
continued for several weeks at a time. These intramuscular injections
were painful and often led to hematomas and sterile abscesses at the
injection site.3,4,23 Adverse effects were observed in around 50% of
patients. Dose-dependent hypertension and tachycardia were most
frequent. Also seen were anxiety, restlessness, nausea and vomiting,
headache, parasthesias, dysesthesias, chest constriction, abdominal
pain, flushing, sweating, conjunctivitis, blepharospasm, lacrimation,
rhinorrhea, and salivation. Approximately 30% of children developed
drug-induced fever.29,30 As BAL was reconstituted in peanut oil, it was
contraindicated in patients with peanut allergies.27 Besides these issues,
the major problem with the use of BAL was development of tach-
yphylaxis with waning clinical benefits and re-emergence of symptoms.
An explanation is that repeated courses of BAL resulted in liver
enzyme induction and auto-oxidation of the two sulfhydryl groups of
the drug and drug tolerance.31
Currently, BAL has almost entirely been replaced in routine clinical
use by the two oral copper chelators, penicillamine and trientine.
Unlike these two, BAL is lipophilic and has good penetration through
the blood–brain barrier. Therefore, some have suggested that BAL
might be helpful as a short-term therapy in patients with severe
neurological disability.23,32,7,31,33 Scheinberg and Sternlieb23,32 (1984,
1995) recommended a 1-month course of BAL in combination with
penicillamine. They advise that 1.5 mL (10% suspension in peanut oil)
of BAL be given twice a day as deep intramuscular injections in the
buttocks (alternating between the right and the left buttock), three to
five times a week. The injections should be given in the top lateral
quadrant of the buttock with subsequent injections two inches below
the previous one. This would allow 10 injections in both buttocks
before the need to return to the original injection site after about
2 weeks. If there are no muscular hematomas the course of BAL may
be extended to a second month after a drug holiday of 1–2 weeks to
prevent tachyphylaxis.23,32. In the last few decades BAL use has been
reported only in isolated case reports.34 There have been no recent
trials or updates of use of BAL for WD.
Unithiol (dimaval; 2,3-dimercapto-1-propane sulfonate [DMPS]) is
a sulfonic acid derivative of BAL that can be administered orally.
Other than a few reports of its use,35–37 there is not enough informa-
tion available about unithiol to provide any recommendations.
Penicillamine. In 1950, while studying amino acid secretion in liver
diseases at the Charles Dent laboratory, University College Hospital,
London, John Walshe identified a new sulfur-containing amino acid
(dimethyl cysteine) in the urine of a patient who had had a recent liver
lobectomy and had received penicillin antibiotic. Later, while working
with Charles Davidson at the Thorndike Memorial Laboratory,
Boston City Hospital, he saw a patient with WD referred by Denny-
Brown for management of liver failure. Based on his prior study,
Walshe conceptualized that dimethyl cysteine had the requisite struc-
ture to chelate copper. As predicted, the compound led to brisk
cupriuresis in the patient. Subsequently, working at the University of
Cambridge, Walshe showed that penicillamine was an effective and
safe oral copper chelator with dramatic and sustained clinical benefit
in patients with WD.38–40
Penicillamine (D-penicillamine, bb dimethyl cysteine, thiovaline)
is a thiol with a sulfhydryl group that binds copper and facilities its
excretion into urine both in normal people and in patients with Wilson
disease.39,41 The D-isomer, referred to as d-penicillamine, is used
clinically (the L-isomer is toxic).7 Oral penicillamine in doses of 1–2 g
per day can initially lead to up to 9 mg of cupriuresis per day in drug
naı¨ve patients.19 The rate of copper excretion with penicillamine is
Table 2. Medical Therapies for Wilson Disease
Drug Mechanism of Action Route of Administration Potential Duration of Therapy
British anti-Lewisite
or dimercaprol1
Copper chelation Deep intramuscular
injection in buttocks
A few weeks or months
with drug-free intervals
Penicillamine Copper chelation Oral Lifelong
Trientine Copper chelation Oral Lifelong
Zinc salts Decreases gastrointestinal
copper absorption
Oral Lifelong
Tetrathiomolybdate2 Copper chelation + Decreases
gastrointestinal copper absorption
Oral A few months2 (see text)
1British anti-Lewisite is no longer used in regular practice as it requires painful intramuscular injections and is associated with serious adverse effects
and tachyphylaxis. There is suggestion for short-term use of British anti-Lewisite in patients with severe neurological disability (see text).
2Under clinical investigation; not commercially available.
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larger than that with BAL.20,30,39 While BAL doubled urinary copper
excretion in two patients with WD, in the same patients, penicillamine
increased urinary copper excretion nine- to 17-fold.30,41 Penicillamine
mobilizes tissue copper stores and long-term use is associated with
normalization of body copper balance. As tissue copper stores decrease,
penicillamine-induced copper excretion decreases, typically by the end
of one year.19,30,42 As opposed to BAL, penicillamine is not associated
with tachyphylaxis.31
Penicillamine is recommended for use in symptomatic patients
during the initial intensive phase of treatment and later as maintenance
therapy. It is also recommended in presymptomatic patients.14–16,22
The therapeutic response is best seen clinically. The liver dysfunction
usually stabilizes and histological improvement has been demonstrated.
Neurological disability reverses in a majority of patients.23,31,43,44 There
is improvement in movement disorders as well as in cognitive and beh-
avioral problems. Patients with severe cognitive and physical disability
can also recover and resume normal lives. Kayser–Fleischer rings
decrease and resolve. This clinical recovery is associated with reduction
of brain magnetic resonance imaging (MRI) abnormalities.23,31,43,45
In most patients penicillamine can be safely administered long term,
with close monitoring for adverse effects and medication compliance.
S.F., the first patient ever to receive penicillamine, recovered from
severe neurological disability and returned to normal life. As per the
last report, she had been on penicillamine for 47 years, raised three
children and continued to be normal.38 Similar good outcomes have
been shown in recent longitudinal studies involving large patient
populations.43,44,46,47 Penicillamine can be given during pregnancy.
In fact, discontinuation of penicillamine during pregnancy has led to
deterioration of WD. Breast-feeding however should be avoided as
penicillamine is excreted in breast milk and may interfere with the
infant’s copper metabolism.14,15,23,48
In symptomatic adults, penicillamine is given in doses up to 1.5–2 g
per day. The dose may be reduced to 500–750 mg per day once
patients have recovered clinically, thus indicating that normal copper
balance has been achieved. The maintenance therapy needs to be
continued lifelong to prevent re-accumulation of dietary copper in the
body. The dose in children is 20 mg/kg/day (rounded to the nearest
250 mg).21 Food reduces penicillamine absorption by over 50%;
therefore the drug should be given on an empty stomach (fasting is
advised; preferably fasting 3–4 hours before and 2–4 hours after the
drug is taken). Separating drug doses from meal times is difficult and
feasible with, at most, twice a day dosing (typically early morning and
midway between lunch and dinner).14,15,21,25 Penicillamine has been
shown to have an antipyridoxine effect. Most clinicians therefore
supplement pyridoxine (vitamin B6) in all patients on penicillamine
though some recommend B6 supplementation only in pregnant
women, and in cases of acute illness or nutritional deficiencies.49,50
Worsening of neurological symptoms soon after starting penicilla-
mine is perhaps the most worrying adverse effect of the drug. The fear
of such a worsening often leads to preemptive under-treatment of
patients. Neurological worsening is reported in around 10% of patients,
though much higher prevalence has also been described.23,43,51–54
Neurological worsening has also been reported with other treatments for
WD including trientine, zinc, ammonium TTM and liver transplant.
Some recent studies suggest that the frequency may be similar for
penicillamine, trientine, and zinc and less than 10%.46,47,52 The mecha-
nism of neurological worsening is unclear and it is not yet possible
to predict which patients may worsen with copper chelation. One
hypothesis is that treatment leads to sudden mobilization of copper from
liver into the blood and then the brain. This released copper may then
lead to free-radical induced tissue injury.53,55 (To mitigate the proposed
free radical surge Walshe31 recommends the addition of oral alpha
tocopherol [vitamin E] as a free radical scavenger during the first
3 months of treatment.) In a recent study, the severity of baseline neuro-
logic disability, concomitant use of antidopaminergic agents, and MRI
lesions in the brainstem and thalamus were associated with increased risk
of neurological worsening.52 In a majority of patients with drug-induced
neurological worsening symptoms remit with brief down-titration of
penicillamine. In others, penicillamine should be discontinued and
replaced by alternative treatment. In rare instances (1–3% or less) the
disability is not reversible.14,15,23,43 Death from fatal status dystonicus
that developed a few weeks after initiation of penicillamine has been
reported.56 Urgent liver transplant as rescue treatment for neurological
deterioration has shown variable results.24 A pragmatic approach to
prevent neurological deterioration is to start penicillamine in low doses
and slowly escalate the doses every few weeks with careful clinical
monitoring. In case of clinical deterioration the doses can be promptly
reduced and then slowly up-titrated on clinical recovery.14,15,25,57
Penicillamine is also associated with some early-onset and late-
onset adverse effects. The early reactions are seen in 10–20% patients,
typically within the first few weeks of drug use, and include fever, skin
rash, lymphadenopathy, and cytopenias. These are dose-dependent
hypersensitivity reactions to penicillamine that abate with down-
titration of the doses, or with a brief course of oral steroids.23,46,58
Early-onset penicillamine induced pancytopenia is rare and necessi-
tates drug withdrawal. In contrast to these early-onset adverse effects,
late reactions are infrequent and are observed after years and decades
of penicillamine use. Though uncommon, late-onset hypersensitivity
reactions are potentially fatal. They include drug-induced lupus
or isolated nephrotic syndrome, leading to transient or progressive
renal failure and in some cases end-stage renal disease. Rare instances
of Goodpasteur’s nephritis, optic neuropathy, arthropathy, or drug-
induced myasthenia have been reported. In case of mild reactions,
down-titration, or temporary drug cessation may be attempted in addi-
tion to symptomatic treatment. However, in case of severe reaction it
may be prudent to withdraw penicillamine immediately and substitute
with trientine.59–66 In a small subset of patients though, similar hyper-
sensitivity-related reactions also develop with the use of trientine. In a
study, elevated serum antinuclear antibodies did not help predict long-
term penicillamine associated immunological reactions.67 Overall,
most of the penicillamine-induced immunological adverse effects can
be managed by concomitant steroids.43,46 On prolonged penicillamine
use, patients may also develop various skin lesions related to inter-
ference of penicillamine with collagen and elastin linking. These are
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rare idiosyncratic reactions and include penicillamine dermatopathy
and elastosis perforans serpiginosa. They are usually of cosmetic con-
cern alone and treated symptomatically. Easy bruising and subcuta-
neous nodules are rare with maintenance doses of less than one gram
per day. Penicillamine related pemphigus lichen planus and painful
stomatitis have also been described.68–75
Trientine. The need for an alternative to penicillamine arose with
reports of penicillamine-induced nephropathy and renal failure in
some patients with WD. Penicillamine had to be discontinued in these
cases, which led to worsening of WD. Other existing treatments,
including BAL and zinc, were not well tolerated and there was fear
that the patients could die from WD without copper chelation.76 Hall
Dixon,77 from the Department of Biochemistry at the University of
Cambridge, suggested use of triethylene tetramine, an industrial che-
mical used for hardening epoxyresin. This is an amine with structure
similar to the naturally occurring amines, spermidine and spermine,
and therefore was presumed safe for use in humans. However, triethy-
lene tetramine is very alkaline with pH 14 and the commercially
available industrial formulation had around 40% impurities including
triaminotriethylamine that is possibly associated with acute tubular
necrosis. Dixon neutralized the amine with hydrochloric acid to gene-
rate crystalline salt, trientine dihydrochloride (triethylene tetramine;
N,N 9-bis(2-aminoethyl)-1,2-ethanediamine, trien).7,77 Trientine dihy-
drochloride, commonly referred to as simply trientine, is very hygro-
scopic and requires airtight storage.7
The four amino groups of trientine form a stable ring complex with
copper, and facilitate cupriuresis. In contrast to BAL and penicilla-
mine, trientine does not have sulfhydryl groups. Trientine was used in
patients after safety was demonstrated in rats.7 Based on clinical and
radiolabeled copper studies Walshe78 showed that trientine led to brisk
urinary copper excretion (at a rate similar to penicillamine) in patients
who are drug naı¨ve, or those who had received only short-term peni-
cillamine treatment and therefore had a large positive copper balance.
In contrast, in patients who had been on long-term penicillamine treat-
ment and therefore did not have a significant positive copper balance,
trientine led to a lesser degree of cupriuresis than penicillamine. He thus
hypothesized that the two drugs chelated copper from different stores in
the body (a store of labile copper and a store of copper that is ‘‘more
firmly attached to tissue proteins’’).78
Trientine was developed as, and has proved to be, a life-saving treat-
ment option in patients in whom penicillamine had to be discontinued
due to adverse events.79–81 Subsequently, trientine has been used suc-
cessfully in patients with decompensated liver failure.82 It is now also
used as a first-line therapy in the initial intensive and the later main-
tenance phase of treatment in symptomatic patients. Trientine is also
recommended in asymptomatic patients with WD. It can be continued
safely as a long-term therapy.46,76,78,81,83–91 Trientine can be given to
pregnant women. It is recommended that breast-feeding be avoided
during trientine treatment (Table 2).14,15,92
As with penicillamine, trientine doses have to be taken at a diffe-
rent time from meal times. Recommended doses for initial intensive
chelation in adult symptomatic patients are 900 mg to 2 g, given in two
to three divided doses. The dose may be reduced to 600–900 mg per
day for maintenance therapy in symptomatic patients, and a similar
dose may be used in adult asymptomatic patients.15,93 In children, the
recommended dose of trientine is 20 mg/kg/day (rounded to the
nearest 300 mg).21 It has been suggested that once-daily trientine
dosing might be sufficient as a maintenance therapy.94,95 If confirmed
in larger studies, such a dosing schedule would help improve patient
compliance with treatment
Trientine, as is true for penicillamine, can lead to neurological
deterioration. In recent studies, the risk of neurological deterioration
with trientine is similar to that with penicillamine.46,52 The symptoms
usually resolve with a reduction of the drug dose.46,86,96 Early-onset
hypersensitivity reactions are less frequent with trientine than with
penicillamine. Among the late-onset hypersensitive reactions, both
drug-induced lupus and nephritis (as with penicillamine) have been
observed with trientine. Management involves dose reduction and use
of steroids. In cases of severe reaction, it is best to substitute trientine
with an alternative treatment.23,25,54,91 Trientine can form toxic com-
plexes with iron and the two should not be given concomitantly.15
There are isolated reports of trientine-induced sideroblastic anemia
that reversed with a reduction in trientine doses.97 Pancolitis, requiring
trientine withdrawal, has also been described.98 Skin rash, loss of taste,
and hemorrhagic gastritis have been reported in patients with primary
biliary cirrhosis receiving trientine.99 There is a report of a patient
developing dizziness and vomiting 24 hours after ingestion of 6 g of
trientine with suicidal intent. The symptoms remitted within 48 hours.100
Tetrathiomolybdate. Molybdenum is an essential micronutrient present
in food. It has long been known in veterinary medicine literature that in
Australia sheep grazing on sulfur-rich and molybdenum-contaminated
pastures developed copper deficiency syndrome (known as ‘teart disease’).
These reports suggested use of molybdates for treatment of WD in the
1940s once it was recognized that WD resulted from copper toxicosis.
However, an early study of molybdenum failed to show clinical or
biochemical benefit in patients.101 An explanation is that unlike the
ovine abomasum (fourth stomach), the human gastric mucosa does not
reduce molybdate to TTM. And, unlike TTM, molybdate does not have
anti-copper properties. In the 1980s when Walshe and Stuart Laurie, an
inorganic biochemist from University of Leicester, were searching for an
alternative treatment of WD, they considered using a reduced form
of molybdate, ammonium TTM, for treatment. To check for possible
adverse effects Walshe7 took the drug himself for a week and having
suffered no ill effects, prescribed it to his patient. This patient who was
intolerant to penicillamine, trientine, and BAL, improved neurologically
with 30 mg twice a day dose of ammonium TTM. And at the end of 1
year of treatment with the drug, his liver histology had normalized.102
Radiocopper studies showed that ammonium TTM (commonly simply
referred to as tetrathiomolybdate or TTM) given orally almost com-
pletely blocks dietary copper absorption by forming complexes with
copper and proteins in the gut lumen. These complexes are not
absorbed by the intestinal cells and are eliminated in the feces. TTM is
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more effective than zinc in preventing dietary copper absorption and,
unlike zinc, its action is immediate. Besides preventing copper absorp-
tion, both parenteral and oral TTM chelates tissue copper by forming
inert complexes with copper and proteins.102 Oncology studies suggest
that TTM may decrease angiogenesis, fibrosis, and inflammation by
inhibiting various copper-dependent cytokines.103,104
A number of dosing regimens have been tried for TTM, all of which
require multiple doses of the drug per day. For instance, six daily doses
have been used, three with meals to prevent dietary copper absorption
and three in-between meals to chelate tissue copper.18,102,105–110
Though there is a report of its use for 8 years,111 present recommen-
dations are that treatment with TTM be limited to a few months.104
The safety and efficacy of TTM have been studied for use as initial
therapy in patients with neurological symptoms.105–109 It has also been
compared with trientine in such patients.18,110 Adverse effects have
been infrequent and included reversible bone marrow depression, rise
in aminotransferases, acute hepatitis, markedly elevated triglycerides
and cholesterol levels, and seizures.106,112,113 TTM-induced copper
deficiency-related cytopenias have also been reported.114 There is
concern about the safety of TTM use in children and adolescents
as TTM has been shown to impair epiphyseal bone growth in animal
studies.111 Drug-induced neurological worsening has been reported
but is possibly less common than that reported with trientine or
penicillamine.18,106,111
In the last 35 years TTM has been used as an experimental drug in
closely monitored research settings.7 Both ammonium TTM, and the
more recently developed choline TTM, are promising therapies for
WD that are under phase 2 and phase 3 multinational clinical trials.
They are not as yet commercially distributed.104
Zinc. Gerrit Schouwink, a Dutch neurologist, in his MD thesis7 for the
University of Amsterdam in 1961, showed that zinc (in the form of zinc
salts) could reduce intestinal absorption of copper and be used for
treatment of WD. Later, zinc therapy was supported and popularized
by Tjaard Hoogenraad and George Brewer.31,115–117
Zinc given orally (as zinc salts) is absorbed by the intestinal cells and
increases production of metallothionein in the cells 25-fold within 2–3
weeks of initiation of therapy. Metallothioneins are cysteine-rich
proteins that can bind various metal ions and are normally present in
the intestine, liver, brain, and other tissues. They have a stronger
affinity for copper than for zinc. The zinc-induced metallothionein
in enterocytes thus preferentially binds to dietary copper and copper
secreted into the gut. The copper bound to metallothionein is seque-
stered within the intestinal cells and prevented from absorption into
the blood. The metal is subsequently lost in feces when the enterocytes
are shed in the intestinal lumen during normal cellular turnover.
Therefore, zinc may cause a slow negative copper balance. Zinc may
also stimulate metallothionein production in the liver.15,118
Zinc is recommended as maintenance therapy in symptomatic
patients once symptoms have regressed following treatment with oral
copper chelators.15 It has also been given as the first-line therapy
in asymptomatic patients.119,120,121 However, there are reports of
deterioration in liver function in asymptomatic patients while on zinc
therapy.122–124 Though zinc is well tolerated by children with WD,125–127
some investigators have raised concerns about the long-term consequences
of use of zinc in children because (unlike oral copper chelators) zinc may
not reduce liver copper content and it has the potential to induce copper
deficiency.14,15
Zinc has also been used at some centers as treatment in patients with
symptomatic liver disease116,117,128–131 and symptomatic neurological
disease.47,132–135 Some studies indicate that patients with liver disease
may be less responsive to zinc than patients with neurological impair-
ment.130,136 Both hepatic and neurological deterioration have been
reported in some symptomatic patients receiving zinc.31,33,47,130,137
Currently, the use of zinc in symptomatic patients is not widely
accepted.138
Zinc is administered as sulfate, acetate, or gluconate salts. These are
given as 150 mg of elemental zinc in adults, or as 75 mg in children, in
two to three divided doses per day.21,120,139 As with penicillamine and
trientine, food interferes with absorption of zinc and therefore zinc
should not be given at meal times. Zinc-induced gastric irritation is
common and limits zinc doses. It is the most common reason for
discontinuation of the drug by patients. Drug tolerance can be
improved by switching to an alternative zinc salt; generally, acetate
and gluconate salts are better tolerated than sulfates. Another strategy
is to give the drug in the mid-morning rather than before breakfast.
Addition of a small protein meal may further mitigate the gastric
symptoms.21,140 Zinc can be safely continued during pregnancy.141
Except for gastric symptoms, zinc has few adverse effects. Zinc can
lead to neurological deterioration after commencement of therapy.
The incidence of such deterioration has been reported to be similar to
that observed with penicillamine and trientine.47,136 The mechanism
of zinc-induced neurological deterioration is unclear and is probably
different from that associated with oral chelators. Zinc can also lead
to anemia, and isolated increases in lipase and amylase have been
described.33,142 There are isolated reports of copper deficiency-related
anemia, neutropenia, sensorimotor neuropathy, or myelopathy that
developed following long-term use of zinc (for treatment of WD or
other illnesses, or as an over-the-counter health supplement). The
myelopathy is characterized by demyelination of dorsal spinal columns,
and is similar to that seen with vitamin B12 deficiency. The biochemical
and clinical features of zinc-induced copper deficiency generally improve
with copper replacement (foods rich in copper) and reduction in zinc
doses,143–145 although there are reports of persistent symptoms despite
copper correction.146,147 (As noted earlier, copper deficiency has also
been described in association with TTM,114 although, to our knowledge,
cases of copper deficiency following treatment with penicillamine or
trientine have not been reported.)
Zinc and oral chelators (penicillamine and trientine) have different
mechanisms of action, which suggests that there may be potential
benefit of using them in combination. On the other hand, there are
pragmatic problems in scheduling the drug doses for such a com-
bination therapy. If given together, the oral copper chelators chelate
zinc and that decreases the bioavailability and efficacy of zinc and
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those of the chelators.148 Thus the oral chelator and zinc have to be
given in multiple daily doses, separated both from meal times and from
each other, which is practically difficult and reduces compliance.149
A few individual studies have found a combination therapy using
zinc and an oral chelator to be beneficial. However, a systematic
review of such combination therapies found that overall they have a
lower rate of effectiveness, a higher rate of adverse effects, and higher
mortality than monotherapies (oral chelator or zinc alone).17 For
example, there is potential risk of severe sideroblastic anemia following
use of zinc with trientine.150 For these reasons the use of combination
therapies is generally not recommended.
Discussion
From the time of introduction of penicillamine, WD has been a
treatable disorder. Patients with WD can be expected to live healthy
and normal lives. If WD is diagnosed in the presymptomatic stage,
symptom onset and copper-related tissue injury can be prevented.14,15
If WD-related neurological disability has already developed at diagnosis,
this too can be reversed in most patients.23,31,43,44,54 WD-related liver
failure can also be stabilized.23,31,43,45
The mainstays of treatment of WD are the two oral chelators,
penicillamine and trientine. Recent, relatively large, patient studies
from various parts of the world have confirmed earlier reports that
both penicillamine and trientine are generally safe and effective. They
also suggest that there is no major difference in the expected clinical
benefits or adverse-effect profile for the two drugs, although no direct
comparative studies have been conducted. At present, therefore, the
choice of drug is governed mainly by their availability and personal
experience in their use. The cost of the drug may also play a role; for
instance, in India trientine has to be imported and is a thousand times
more expensive than penicillamine, which is manufactured locally.
Zinc is another treatment option during the maintenance phase of
treatment, and TTM is a promising alternative currently being
studied.
However, all currently available WD treatments are associated with
adverse effects (such as neurological worsening) in a subset of patients,
which can require adjustment, substitution, or even discontinuation of
treatment. These adverse effects also reduce the patient’s compliance
with treatment, which by itself can lead to clinical deterioration
and even death.6,57,151–153 An approach to deal with this issue is to
systematically monitor the patient under treatment so that treatment
effectiveness, adverse effects, and treatment non-compliance are
tracked and the treatment adjusted accordingly. In recent years, two
WD-specific clinical scales, the Unified Wilson Disease Rating Scale
(UWDRS) and the Global Assessment Scale for Wilson Disease (GAS
for WD), have been introduced for this purpose.154–156
Another complementary approach is to pre-emptively identify the
subset of patients that can be expected to experience adverse effects.
Clinical studies to identify markers for such patients are at a pre-
liminary stage. These efforts have benefited from the improvement in
study design and increase in study size that has been seen in recent
years. Growth of WD referral centers and international multicenter
collaborative projects has made such large studies increasingly feasible.
Besides clinical, imaging, and biochemical markers, genotyping is
also a potential tool for selecting treatment for WD patients. Recent
mapping studies have shown that the ATP7B mutation shows geogra-
phical variance.157,158 And genotype–phenotype analysis in cell models
indicates that certain mutations are associated with more severe
phenotypes than seen with other mutations.158 This mutation-specific
variance has been reported at the cellular level to correlate with the
degree of loss of ATP7b protein function.159,160 In the future, such
research developments can be expected to move to the clinical stage
and allow one to predict the likely disease course and drug response in
individual patients, and thus tailor treatment.
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